Innovative clinical trial design for pediatric therapeutics |
| |
Authors: | Laughon Matthew M Benjamin Daniel K Capparelli Edmund V Kearns Gregory L Berezny Katherine Paul Ian M Wade Kelly Barrett Jeff Smith Phillip Brian Cohen-Wolkowiez Michael |
| |
Affiliation: | School of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. |
| |
Abstract: | Until approximately 15 years ago, sponsors rarely included children in the development of therapeutics. US and European legislation has resulted in an increase in the number of pediatric trials and specific label changes and dosing recommendations, although infants remain an understudied group. The lack of clinical trials in children is partly due to specific challenges in conducting trials in this patient population. Therapeutics in special populations, including premature infants, obese children and children receiving extracorporeal life support, are even less studied. National research networks in Europe and the USA are beginning to address some of the gaps in pediatric therapeutics using novel clinical trial designs. Recent innovations in pediatric clinical trial design, including sparse and scavenged sampling, population pharmacokinetic analyses and 'opportunistic' studies, have addressed some of the historical challenges associated with clinical trials in children. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|